An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03692897|
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : October 22, 2018
|Condition or disease||Intervention/treatment|
|Hepatitis B Hepatitis Liver Diseases||Other: TAF|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection|
|Estimated Study Start Date :||October 2018|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
Patients with a medication history of tenofovir alafenamide (TAF).
Patients who have a medication history of TAF
- Profile of patients with chronic HBV infection as measured by a review of concurrent medications, co-morbidities, medical history, staging of liver disease, and additional available clinical results. [ Time Frame: Three year retrospective review. ]Additional results may include AFP, serology results (HBsAg, HBeAg, Anti-HBe, HBV DNA, HBV genotype and precore mutation, HDV) and radiology/histology reports (liver biopsy grade/stage, FibroScan®, MRE, ultrasound).
- Efficacy of chronic HBV treatments as indicated by HBV DNA suppression measurements. [ Time Frame: Three year retrospective review. ]Efficacy will also be measured via ALT normalization, HBeAg loss, HBsAg loss, HBeAg and HBsAg seroconversion, development of HCC or evidence of hepatic decompensation.
- Safety of chronic HBV treatments on renal function as assessed by serum creatinine. [ Time Frame: Three year retrospective review. ]Renal function will also be measured via eGFRCG, proteinuria, albuminuria, serum phosphorus.
- Safety of chronic HBV treatments on bone density as assessed by DEXA scan. [ Time Frame: Three year retrospective review. ]Bone density will also be measured via medical history of osteopenia, osteoporosis, fractures.
- Safety of chronic HBV treatments as measured by co-morbidities and adverse events. [ Time Frame: Three year retrospective review. ]Safety will be assessed by reviewing medical history for evidence of adverse events, such as cardiovascular disease, diabetes mellitus, hypertension, hyperlipidemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03692897
|Contact: Chloe Katz, MPH, MSHS||(984) 234-0268 ext firstname.lastname@example.org|
|United States, California|
|California Liver Research Institute||Recruiting|
|Pasadena, California, United States, 91105|
|Contact: Stephanie Tang 626-795-5769|